LMO2 is an intrinsically disordered transcription factor activated in T cell leukaemia that is difficult to target. It forms part of a multiprotein complex that has bipartite DNA binding through ...

An expert explains that T-cell fitness is critical for CAR T-cell therapy success, as earlier use—before multiple rounds of chemotherapy or bispecific antibody exposure—helps preserve T-cell quality ...

An expert discusses that while CAR T-cell therapies carry risks such as cytokine release syndrome and neurotoxicity, advancements in supportive care and monitoring have significantly improved their ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

Acuitas Therapeutics has announced the publication of a new study in Science Immunology, titled "An IL12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses." ...

Background Cholangiocarcinoma (CCA) is a highly lethal malignant tumour with increasing incidence. Current therapies exhibit ...

To understand how DJ-1 hydrolyzes cyclic 3-phosphoglyceric anhydride—a highly reactive, toxic cellular metabolite—researchers ...

The findings improve the understanding of how mitochondria support proper T-cell function and could inform the development of new targeted immunotherapies.

In fighting chronic infections or certain cancers, CD8+ T cells—the immune system's frontline soldiers—eventually become exhausted. They lose effectiveness and respond less efficiently to ...

An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a Phase I clinical trial has shown.

A comparison of the bone marrow cells from healthy and CML donors showed an increase in the CD8 T cell population along with a decrease in the CD4 T cell population in CML patients, indicating ...